Cite this article:
Sufiyan Ansari*, Dr. G.J. Khan. Navigating the Biosimilars Landscape: Regulatory, Clinical, Market, Patient, and Provider Perspectives and Future Directions. IJRPAS, Sep-Oct 2023; 2(5): 26-39.
1. Biopharmaceuticals in perspective fall [Internet].
Document from Pharma-org [updated at 16th July 2018] Available from:
https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/A-C/ChartPack_Biopharmaceuticals_in_Perspective_Fall2020.pdf
2. Delivering on the potentials of Biosimilar medicine
[Internet]. Document from EMA [updated at 1st March 2018] Available
from:https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf
3. Joshi D, Khursheed R, Gupta S, Wadhwa D, Singh TG,
Sharma S, Porwal S, Gauniyal S, Vishwas S, Goyal S, Gupta G, Eri RD, Williams
KA, Dua K, Singh SK. Biosimilars in Oncology: Latest Trends and Regulatory
Status. Pharmaceutics. 2022 Dec 5;14(12):2721. doi:
10.3390/pharmaceutics14122721. PMID: 36559215; PMCID: PMC9784530.
4. Cargnin S, Shin JI, Genazzani AA, Nottegar A,
Terrazzino S. Comparative efficacy and safety of trastuzumab biosimilars to the
reference drug: a systematic review and meta-analysis of randomized clinical
trials. Cancer Chemother Pharmacol. 2020 Nov;86(5):577-588. doi: 10.1007/s00280-020-04156-3.
Epub 2020 Oct 1. PMID: 33005979.
5. van Aerts LA, De Smet K, Reichmann G, van der Laan
JW, Schneider CK. Biosimilars entering the clinic without animal studies. A
paradigm shift in the European Union. MAbs. 2014;6(5):1155-62. doi: 10.4161/mabs.29848.
PMID: 25517301; PMCID: PMC4622966.
6. Questions and Answers on Biosimilar Development and
the BPCI Act Guidance for Industry [Internet]. Guidance document from US FDA
[updated at 2021 September] Available from: https://www.fda.gov/media/119258/download
7. Guidelines on evaluation of biosimilars [Internet].
WHO [updated at 2022-24-12; Published at 2021-05-11] Available from: https://cdn.who.int/media/docs/default-source/biologicals/who-guidelines-on-evaluation-of-biosimilars---4-nov-2021.pdf?sfvrsn=f17799ae_5
8. Biosimilars [Internet]. Document from US FDA
[updated at 03/01/2023] Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
9. Biosimilar medicines: Overview [Internet]. Document
from EMA [updated at 26/04/2023] Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview
10. Biosimilar medicines: Overview [Internet].
Document from EMA [updated at June 21- 2023] Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview
11. Łosińska K, Korkosz M, Pripp AH, Haugeberg G.
Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis
patients naïve to or switched from reference rituximab. Rheumatol Int. 2023
May;43(5):881-888. doi: 10.1007/s00296-023-05307-4. Epub 2023 Mar 16. PMID:
36922417; PMCID: PMC10017342.
12. Zhao Z, Zhao L, Xia G, Lu J, Shen B, Zhou G, Wu F,
Hu X, Feng J, Yu S. Efficacy and safety of bevacizumab biosimilar compared with
reference bevacizumab in locally advanced and advanced non-small cell lung
cancer patients: A retrospective study. Front Oncol. 2023 Jan 9; 12:1036906.
doi: 10.3389/fonc.2022.1036906. PMID: 36698393; PMCID: PMC9868544.
13. Lu X, Hu R, Peng L, Liu M, Sun Z. Efficacy and
Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid
Arthritis. Front Immunol. 2021 Apr 6; 12:638444. doi:
10.3389/fimmu.2021.638444. PMID: 33889152; PMCID: PMC8055954.
14. Thill M. Biosimilar Trastuzumab in Clinical
Trials: Differences or Not? Breast Care (Basel). 2019 Mar;14(1):17-22. doi:
10.1159/000496503. Epub 2019 Jan 30. PMID: 31019438; PMCID: PMC6465702.
15. Global Medicine Spending and Usage Trends: Outlook
to 2025 - IQVIA [Internet]. IQVIA [updated at 28 April 2021] Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends-outlook-to-2025
16. Biosimilars in the EU [Internet]. IQVIA [updated
at Sep 29, 2020] Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends-outlook-to-2025
17. Biosimilars Biological product payment [Internet]
U.S. Centers for Medicare & Medicaid Services [updated at Sep 19, 2022].
Available from: https://innovation.cms.gov/initiatives/biosimilar-pirs-model/
18. Mulcahy A, Buttorff C, Finegold K, El-Kilani Z,
Oliver JF, Murphy S, Jessup A. Projected US savings from biosimilars,
2021-2025. Am J Manag Care. 2022 Jul;28(7):329-335. doi:
10.37765/ajmc.2022.88809. PMID: 35852882.
19. González-Gay MA, Castañeda S, Ancochea J. Biologic
Therapy in COVID-19. Arch Bronconeumol. 2021 Jan; 57:1-2. doi:
10.1016/j.arbres.2020.06.007. Epub 2020 Jun 26. PMID: 34629622; PMCID:
PMC7318980.
20. The Impact of Biosimilar Competition in Europe
[Internet]. IQVIA [updated at Dec, 2021] Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf
21. Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare
professionals' perceptions and perspectives on biosimilar medicines and the
barriers and facilitators to their prescribing in UK: a qualitative study. BMJ
Open. 2018 Nov 18;8(11): e023603. doi: 10.1136/bmjopen-2018-023603. PMID:
30455389; PMCID: PMC6252648.
22. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale
SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic
Literature Review of Clinical Outcomes. Drugs. 2018 Mar;78(4):463-478. doi:
10.1007/s40265-018-0881-y. PMID: 29500555; PMCID: PMC5854749.
23. Hu R, Yuan T, Wang H, Zhao J, Shi L, Li Q, Zhu C,
Su N, Zhang S. Efficacy, safety and immunogenicity of etanercept biosimilars
versus reference biologics in patients with rheumatoid arthritis: A
meta-analysis. Front Pharmacol. 2023 Feb 16; 14:1089272. doi:
10.3389/fphar.2023.1089272. PMID: 36874005; PMCID: PMC9979087.
24. Papamichael K, Lin S, Moore M, Papaioannou G,
Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv
Chronic Dis. 2019 Mar 26; 10:2040622319838443. doi: 10.1177/2040622319838443.
PMID: 30937157; PMCID: PMC6435871.
25. Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The
Importance of Healthcare Provider Education. Pharmaceut Med. 2021
Jul;35(4):215-224. doi: 10.1007/s40290-021-00396-7. Epub 2021 Aug 22. PMID:
34420201; PMCID: PMC8421278.
26. Baker JF, Leonard CE, Lo Re V 3rd, Weisman MH,
George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health
Administration Settings: Influence of Institutional Incentives. Arthritis
Rheumatol. 2020 Jul;72(7):1067-1071. doi: 10.1002/art.41277. Epub 2020 May 5.
PMID: 32253823; PMCID: PMC7329608.
27. Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan
AM, Bose A. Biosimilars: Key regulatory considerations and similarity
assessment tools. Biotechnol Bioeng. 2017 Dec;114(12):2696-2705. doi:
10.1002/bit.26438. Epub 2017 Sep 19. PMID: 28842986; PMCID: PMC5698755.
28. Chadwick L, Zhao S, Mysler E, Moots RJ. Review of
Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. Curr
Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0. PMID:
30411183; PMCID: PMC6244902.
29. Mulcahy AW, Hlavka JP, Case SR. Biosimilar Cost
Savings in the United States: Initial Experience and Future Potential. Rand
Health Q. 2018 Mar 30;7(4):3. PMID: 30083415; PMCID: PMC6075809.